Key facts
- It has raised $450K; the latest was Seed Round ($200K) in Feb 2026.
- Notable investors include National Institutes of Health, Innovate Carolina.
- Eldec Pharmaceuticals has filed 1 Form D with the SEC, most recently Feb 2026 ($200K sold to 1 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Eldec Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Eldec Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eldec Pharmaceuticals
Developer of anti-inflammatory peptides for the treatment of chronic lung disease. The company's lead development candidate is a fully optimized peptidomimetic that negatively regulates Orai1 levels in lung immune cells and exhibits beneficial immunomodulation function in a wide range of animal models of excessive inflammation, enabling the prevention of an exuberant immune response, and helps clear pathogens from the lung.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2017
- Website
- eldecpharmaceuticals.com/
- Ownership
- Privately Held (backing)
Eldec Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eldec Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eldec Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.